

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MAXNERVA
雲智匯科技服務

MAXNERVA TECHNOLOGY SERVICES LIMITED
雲智匯科技服務有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 1037)

**SUPPLEMENTAL ANNOUNCEMENT
IN RELATION TO THE ANNUAL REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024**

Reference is made to the annual report of Maxnerva Technology Services Limited (the “**Company**”, together with its subsidiaries collectively referred to as the “**Group**”) for the year ended 31 December 2024 which was published on 28 April 2025 (the “**2024 Annual Report**”). Unless the context otherwise defined, capitalised terms in this announcement shall have the same meanings as those defined in the 2024 Annual Report.

The board of directors of the Company (the “**Board**”) would like to provide the following supplemental information in relation to the Share Option Scheme, which is set out in the subsection headed “Summary of the 2023 Share Option Scheme” under the section headed “Share Option Scheme” in the Report of the Directors from page 73 to page 75 and note 27 to the Consolidated Financial Statements from page 166 to page 170 of the 2024 Annual Report:

Price payable on application or acceptance of the share option and the period within which payments or calls must or may be made or loans for such purposes must be repaid

A non-refundable amount of HK\$1.00 (or such non-refundable nominal sum in any currency as the board may determine) shall be paid by eligible participant in favour of the Company on acceptance of an offer of the share option. The offer shall remain open for acceptance by the eligible participant for a period of 21 days from the date upon which it is made.

Vesting period

Note 27 Share Option Scheme

Movement of the options granted under the share option scheme for the year ended 31 December 2024 are as follows:

Date of grant	Name or category of participants	Number of share options					Outstanding as at 31 December 2024	Vesting period	Exercise period	Exercise price per share option HK\$	Closing price per share immediately before the grant date of share option HK\$
		Outstanding as at 1 January 2024	Granted during the year	Expired during the year	Forfeited during the year	Exercised during the year					
Director											
31 August 2017	Mr. CHENG Yee Pun	300,000	-	-	-	-	300,000	31 August 2017 to 30 August 2019	31 August 2019 to 30 August 2027	1.684	1.55
12 November 2018	Mr. CHENG Yee Pun	500,000	-	-	-	-	500,000	12 November 2018 to 11 November 2020	12 November 2020 to 11 November 2028	0.686	0.66
8 April 2022	Mr. CHENG Yee Pun	500,000	-	-	-	-	500,000	8 April 2022 to 7 April 2024	8 April 2024 to 7 April 2032	0.310	0.31
		<u>1,300,000</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>1,300,000</u>				
Employees											
31 August 2017	Continuous contract employees	2,850,000	-	-	(1,800,000)	-	1,050,000	31 August 2017 to 30 August 2019	31 August 2019 to 30 August 2027	1.684	1.55
12 November 2018	Continuous contract employees	4,460,000	-	-	(1,440,000)	-	3,020,000	12 November 2018 to 11 November 2020	12 November 2020 to 11 November 2028	0.686	0.66
8 April 2022	Continuous contract employees	6,610,000	-	-	(430,000)	-	6,180,000	8 April 2022 to 7 April 2024	8 April 2024 to 7 April 2032	0.310	0.31
		<u>13,920,000</u>	<u>-</u>	<u>-</u>	<u>(3,670,000)</u>	<u>-</u>	<u>10,250,000</u>				
		<u>15,220,000</u>	<u>-</u>	<u>-</u>	<u>(3,670,000)</u>	<u>-</u>	<u>11,550,000</u>				

Movement of the options granted under the share option scheme for the year ended 31 December 2023 are as follows:

Date of grant	Name or category of participants	Number of share options					Outstanding as at 31 December 2023	Vesting period	Exercise period	Exercise price per share option HK\$	Closing price per share immediately before the grant date of share option HK\$
		Outstanding as at 1 January 2023	Granted during the year	Expired during the year	Forfeited during the year	Exercised during the year					
Director											
31 August 2017	Mr. CHENG Yee Pun	300,000	-	-	-	-	300,000	31 August 2017 to 30 August 2019	31 August 2019 to 30 August 2027	1.684	1.55
12 November 2018	Mr. CHENG Yee Pun	500,000	-	-	-	-	500,000	12 November 2018 to 11 November 2020	12 November 2020 to 11 November 2028	0.686	0.66
8 April 2022	Mr. CHENG Yee Pun	500,000	-	-	-	-	500,000	8 April 2022 to 7 April 2024	8 April 2024 to 7 April 2032	0.310	0.31
8 April 2022	Mr. CAI Liting	800,000	-	-	-	-	800,000	8 April 2022 to 7 April 2024	8 April 2024 to 7 April 2032	0.310	0.31
		<u>2,100,000</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>2,100,000</u>				
Employees											
31 August 2017	Continuous contract employees	3,050,000	-	-	(200,000)	-	2,850,000	31 August 2017 to 30 August 2019	31 August 2019 to 30 August 2027	1.684	1.55
12 November 2018	Continuous contract employees	4,760,000	-	-	(300,000)	-	4,460,000	12 November 2018 to 11 November 2020	12 November 2020 to 11 November 2028	0.686	0.66
8 April 2022	Continuous contract employees	6,210,000	-	-	(400,000)	-	5,810,000	8 April 2022 to 7 April 2024	8 April 2024 to 7 April 2032	0.310	0.31
		<u>14,020,000</u>	<u>-</u>	<u>-</u>	<u>(900,000)</u>	<u>-</u>	<u>13,120,000</u>				
		<u>16,120,000</u>	<u>-</u>	<u>-</u>	<u>(900,000)</u>	<u>-</u>	<u>15,220,000</u>				

The information contained in this supplemental announcement does not affect other information contained in the 2024 Annual Report. Save as disclosed above, all other information in the 2024 Annual Report remains unchanged.

By order of the Board
Maxnerva Technology Services Limited
CHANG Chuan-Wang
Chairman

Hong Kong, 22 October 2025

As at the date of this announcement, the Board comprises two executive directors, namely, Mr. CHANG Chuan-Wang and Mr. CHENG Yee Pun, three non-executive directors, namely, Mr. KIM Hyun Seok, Mr. CHANG Kuo-Chin and Ms. HUANG Pi-Chun, and three independent non-executive directors, namely, Mr. KAN Ji Ran Laurie, Prof. ZHANG Xiaoquan and Mr. KAM Chi Sing.